Insider Transactions
| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Aug 12, 2021 | SVP/GM, Vascular Access | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 2,395 | -- | 29,056 | |
| Aug 12, 2021 | SVP/GM, Vascular Access | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,195 | -- | -- | |
| Aug 12, 2021 | SVP/GM, Vascular Access | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 8,210 | -- | 34,871 | |
| Aug 12, 2021 | SVP/GM, Vascular Access | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 7,079 | -- | -- | |
| Aug 12, 2021 | Director, President and CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 19,387 | -- | 378,554 | |
| Aug 12, 2021 | Director, President and CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 50,139 | -- | -- | |
| Aug 12, 2021 | Director, President and CEO | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 40,528 | -- | 399,695 | |
| Aug 12, 2021 | Director, President and CEO | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 34,938 | -- | -- | |
| Aug 12, 2021 | SVP Global Operations and R&D | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 2,685 | -- | 24,507 | |
| Aug 12, 2021 | SVP Global Operations and R&D | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,945 | -- | -- |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.